The Nueva Ecija cardiovascular risk experiment: An evaluation of the impact of risk information and screening on primary prevention of cardiovascular disease
How to cite
O'Donnell, Owen; Capuno, Joseph. 2018. "The Nueva Ecija cardiovascular risk experiment: An evaluation of the impact of risk information and screening on primary prevention of cardiovascular disease." AEA RCT Registry. AEARCTR-0002867. https://doi.org/10.1257/rct.2867-2.0
Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.
* Primary investigator
Abstract
This study seeks to assess how beliefs about health risks, specifically the risk of cardiovascular disease (CVD), affect health lifestyles and the demand for preventive care in a low-income setting. It also aims to establish the effectiveness of the Package of Essential Noncommunicable Disease Interventions in the Philippines (PhilPEN) in delivering primary prevention of CVD.
To realize the first objective, we will measure the accuracy of beliefs about exposure to CVD risk and, subsequently, randomly provide information on personal CVD risk based on measured risk factors. This will allow assessment of the extent to which biased beliefs constrain demand for primary prevention and sustain unhealthy lifestyles. In addition, we will test whether beliefs about susceptibility to CVD are responsive to the receipt of information on personal risk, and whether health behaviors and the demand for CVD screening and medication are affected by any revision of beliefs.
To meet the second objective we will randomly encourage uptake of the PhilPEN program’s risk screening by offering entry to a money prize lottery conditional on attending a health clinic where the program operates. The induced random variation in clinic attendance will be used to estimate the program's impact on exposure to risk factors, medication of hypertension, the predicted risk of CVD and awareness of this risk.
Meeting both objectives will allow us to distinguish between scenarios. One is that PhilPEN is effective in preventing CVD of patients who access the program but its impact on population health is muted because poor information on susceptibility to CVD reduces the demand for primary prevention. Another is that even if improved information is effective in raising this demand, this will have little impact on population health through PhilPEN because of deficiencies in the operation of the program in health facilities.
Within the Nueva Ecija province, we will randomly sample barangays (N=304), subsequently households (n=5019) and, finally, one person aged 40-70 within each household. At the barangay level, we will randomly allocate to a treatment group receiving the lottery incentive to attend a health clinic (n=2261), another treatment group receiving information on personal CVD risk (n=497) and a control group (n=2261). A baseline survey (January-April 2018) will record data on initial health, health behavior, health knowledge, risk perceptions, risk attitudes, time preferences, health care utilization and expenditure and socioeconomic characteristics, and deliver the treatments. A follow-up survey 9-12 months later will record outcomes.
Intervention
Two interventions will be randomly allocated: 1) the provision of information on CVD risk, and 2) the offer of a lottery ticket conditional on going for a checkup at a health clinic.
1) Information on CVD risk
Respondents will receive information on the predicted probability of having a heart attack or stroke within 10 years. The predictions will be obtained from the Globorisk tool (www.globorisk.org). All information will be provided within a risk perceptions module of the baseline survey. Only this module will differ across the two treatment groups (information and lottery) and the control group. Information obtained from earlier modules will be retrieved automatically and used to make predictions of CVD risk consistent with the risk factor profile of the respondent.
Three types of information on CVD risks will be provided: a CVD base rate, a personalized CVD risk and an optimal CVD risk. The CVD base rate will be predicted from the respondent’s age and sex only. This information will be provided immediately after the respondents are asked to report the chance of someone of their age and gender having a heart attack or a stroke within ten years, and immediately before being asked to report the chance that they will have a heart attack or stroke within that period. The respondents will be presented with the information both as a chance of X in 100 and as the number of people (X) out of 100 the same age and sex as the respondent that doctors would expect to have a heart attack or stroke within ten years. In addition, a visual aid (sliding ruler) will be used to deliver the information.
After reporting their own chance of having a heart attack or stroke within ten years, the respondents in the treatment group will be told the risk for someone with the same age, sex, smoking status, body mass index (BMI) and blood pressure as them. Each respondent will not be told that this is their own chance of having a heart attack or stroke. Rather, if the respondent is female, she will be told that out of 100 women her age, with the same weight and blood pressure as her, and who (don’t) smoke like her, doctors would expect X to have a heart attack or stroke within 10 years. Analogous information will be provided to male respondents. After being given this information, the respondent is asked again to report their 10-year CVD risk. This is interpreted as the posterior belief (after the provision of personalized information).
Finally, a treatment group respondent will receive information on what the 10-year CVD risk would be for someone of the same age and gender who did not smoke, and had normal blood pressure and BMI. This will be presented as the optimal risk that could be achieved through primary prevention. If the respondent’s risk is above the optimal, then they will be told the reason(s) for this - smoking, above a healthy weight or blood pressure reading is above normal. If the respondent’s risk is not above the optimal, then they will be congratulated and advised how to keep the risk low.
2) Lottery incentive to attend health clinic
Respondents will be offered a ticket for a lottery with a money prize on condition that they visit a specific public health clinic for a checkup. There will be one prize per barangay giving each respondent a one in ten chance of winning P5000 (US$100). The prize is equivalent to approximately 14 days earnings at the regional minimum wage. There is no supply-side component to the intervention. Respondents will simply be told that they can enter a lottery if they go to the specified clinic for a checkup. The health facilities will be told to conduct an assessment deemed appropriate for any particular patient that requests to be issued with a lottery ticket. No instructions will be given that the facilities should follow the PhilPEN protocol. We will evaluate whether they do implement the protocol for patients who qualify (by age if nothing else) for full risk screening.
Prior approval of the study and intervention will be obtained from Mayors and Medical Health Officers. The study team will identify a point person in each health clinic and liaise with them to identify respondents who appear at each clinic. Respondents will be given a voucher at the baseline interview informing them of their entitlement to enter the lottery on attending a clinic. At the clinic, they will exchange the voucher for a lottery ticket. They will be instructed to send an SMS to a number accessed by the study team after obtaining a lottery ticket.
The detailed logistics for the operation of the lottery are providing in the study protocol available that can be downloaded from this website.
Experimental design
The study is a randomized parallel experiment with two separate, non-overlapping treatment groups and one control group. Randomized assignment of treatment will be done at the level of the barangay, which is the smallest administrative unit in the Philippines roughly equivalent to an electoral ward. The 847 barangays in the Nueva Ecija province will be stratified by urban/rural classification. Within each stratum, barangays will be drawn by simple random sampling and randomly allocated to the lotttery treatment (n=137), information treatment (n=30), control (n=137) and those not surveyed (n=543).
Within a barangay, interval sampling will be used: starting from a random location, a procedure will be followed to randomly select households moving out from that point. Selected households will be screened to establish whether each includes anyone aged from 40 to 70 inclusive. If so, one such person will be randomly selected as the main survey respondent and the potential subject of the intervention in the treatment group barangays. Further screening will be undertaken to establish whether the selected person is eligible for the study, mainly on the basis of CVD history. In addition to the main respondent, we will ask the head of household, spouse or other adult to answer questions about the household in general.
We will aim to have 10 persons per barangay completing both the baseline and endpoint surveys and eligible for the treatments. To achieve this, allowing for attrition and non-eligibility, we will survey 17 households per barangay.
The baseline survey (January-April 2018) will record data on initial health, health behavior, health knowledge, risk perceptions, risk attitudes, time preferences, health care utilization and expenditure and socioeconomic characteristics, and deliver the treatments. The end-point survey 9-12 months later will record outcomes.
Design details
Cited by
No citation data available for this registration yet.